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Abstract This article studies a general joint model for longitudinal measurements
and competing risks survival data. The model consists of a linear mixed effects
sub-model for the longitudinal outcome, a proportional cause-specific hazards frailty
sub-model for the competing risks survival data, and a regression sub-model for the
variance–covariance matrix of the multivariate latent random effects based on a mod-
ified Cholesky decomposition. The model provides a useful approach to adjust for
non-ignorable missing data due to dropout for the longitudinal outcome, enables anal-
ysis of the survival outcome with informative censoring and intermittently measured
time-dependent covariates, as well as joint analysis of the longitudinal and survival
outcomes. Unlike previously studied joint models, our model allows for heterogeneous
random covariance matrices. It also offers a framework to assess the homogeneous
covariance assumption of existing joint models. A Bayesian MCMC procedure is
developed for parameter estimation and inference. Its performances and frequentist
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properties are investigated using simulations. A real data example is used to illustrate
the usefulness of the approach.
Keywords Cause-specific hazard · Bayesian analysis · Cholesky decomposition ·
Mixed effects model · MCMC · Modeling covariance matrices
1 Introduction
Joint modeling of longitudinal and survival data has received a great deal of atten-
tion in the past decades in many studies in which both a longitudinal outcome during
follow-up and the occurrence of some key events are recorded. In the statistical lit-
erature, joint models have been proposed to adjust inferences on longitudinal mea-
surements in the presence of non-ignorable missing values due to dropout (Schluchter
1992; DeGruttola and Tu 1994; Little 1995; Hogan and Laird 1997; Henderson et al.
2000; Elashoff et al. 2007, 2008; Hu et al. 2009); to solve difficulties in Cox pro-
portional hazards model arising from time-dependent covariates which are possibly
missing at some event times or subject to substantial measurement error (Faucett
and Thomas 1996; Wulfsohn and Tsiatis 1997; Faucett et al. 1998; Wang and Taylor
2001; Xu and Zeger 2001; Song et al. 2002; Brown and Ibrahim 2003; Tseng et al.
2005; Ye et al. 2008); and to assess covariates effects on both endpoints simultaneously
(Henderson et al. 2000; Zeng and Cai 2005; Elashoff et al. 2007, 2008; Liu et al. 2008).
All the aforementioned joint models assume that the random effects covariance
matrix is the same for all subjects. However, examining whether this matrix is the
same for all subjects (homogeneous) or whether it differs depending on subject-
specific characteristics (heterogeneous) is often neglected in the modeling. Further-
more, ignoring the heterogeneity can result in biased estimates of the fixed and random
effects for the longitudinal outcome (Heagerty and Kurland 2001; Daniels and Zhao
2003). Accounting for heterogeneity in covariance matrices has been discussed by
serval authors in the field of generalized linear regression models (Chiu et al. 1996),
non-linear mixed models (Davidian and Giltinan 1995), and linear mixed models
(Pourahmadi and Daniels 2002; Lin et al. 1997; Zhang and Weiss 2000; Daniels and
Zhao 2003). Nonetheless, no work has been done on modeling the entire random
effects covariance matrix for the joint models.
In this paper, we propose an approach that allows heterogeneous random effects
covariance matrix within the framework of joint analysis of longitudinal measure-
ments and competing risks failure time data. In our joint model, a linear mixed effects
sub-model is used to characterize the longitudinal measurements, a cause-specific
hazards frailty sub-model for the competing risks survival data (Prentice and Breslow
1978), together with a regression sub-model for the joint multivariate random effects
covariance matrix which links the first two sub-models. Specifically, we first use a
modified Cholesky decomposition to decompose the covariance matrix into a lower-
triangular matrix and a diagonal matrix, and then model these matrix entries using
regression models (Pourahmadi 1999; Daniels and Zhao 2003). By jointly modeling
the random effects covariance matrices, our model is distinct from previously stud-
ied joint models (e.g. Hu et al. 2009) that consist of only two sub-models for the
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longitudinal and survival outcomes respectively. Our model has several advantages.
First of all, unlike existing joint models that assume a homogeneous covariance matrix,
our model allows for heterogeneous covariance matrices. Secondly, as discussed in the
remark of Sect. 2, our model includes homogeneous models as special cases. Thirdly,
the covariance model enables dimension reduction. With different choices of regres-
sion covariates, it provides a flexible means to model the heterogeneity and reduce
the number of variance–covariance parameters to be estimated. Forthly, the result-
ing estimated covariance matrices of the multivariate random effects are guaranteed
to be positive definite, which is not always the case for other existing joint models.
Finally, our model provides a useful framework to assess the homogeneous covariance
assumption of existing joint models which is otherwise untestable. Likelihood-based
inference for our model is rather challenging with high-dimensional random effects.
We develop a Bayesian MCMC algorithm to fit the joint model. Gibbs sampling tech-
nique, together with Metropolis-Hastings sampling and adaptive rejection sampling
(ARS) methods, is used to draw random samples from the full conditional distributions
of parameters. With the Bayesian approach, prior information can be incorporated in
a natural way. If no prior information is available, we recommend noninformative
priors for parameters to allow data to dominate the determination of the posterior
distributions.
This paper is organized as follows: in Sect. 2 we describe the joint model formula-
tion. In Sect. 3 we develop the Bayesian estimation and inference methods. In Sect. 4,
a real data application is illustrated using the data from the Scleroderma clinical trial
(Tashkin et al. 2006). In Sect. 5, the performance of our method is examined by simu-
lation studies. Some concluding remarks are provided in Sect. 6. Details of the MCMC
algorithm are deferred to the Appendix.
2 Joint model
Our joint model consists of three components: a linear mixed effect model for the
longitudinal measurements, a cause-specific hazards model for the competing risks
survival data, and a regression model for the variance–covariance matrix of the mul-
tivariate latent random effects based on a modified Cholesky decomposition.
2.1 Longitudinal sub-model
Suppose there are m subjects in the study. For the i th subject at time t , the longitudinal
outcome Yi (t) follows a linear mixed effects model:
Yi (t) = X (1)i (t)T β + Zi (t)T Ui + i (t) (1)
where X (1)i (t) and Zi (t) are vectors of covariates associated with the fixed effects
β (p×1) and the random effects Ui (q ×1) respectively. We assume that the measure-
ment error i (t), which is distributed as N (0, σ 2), is independent of Ui and i (t1) ⊥
i (t2) for any t1 = t2.
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2.2 Cause-specific hazards sub-model
During follow-up, each subject may experience one of g distinct competing causes of
failure or may be right censored. Let Ci = (Ti , Di ) be the competing risks survival
data on subject i , where Ti is the failure or censoring time, and Di assumes a value
from 0, 1, . . . , g, with Di = 0 indicating a noninformative censored event and Di = k
indicating the kth failure type, k = 1, . . . , g. Dependent (or informative) censoring is
treated as one of the g types of failures. The cause-specific hazards sub-model for the
competing risks survival data is specified as follows:











T γk + νkυi
}
.
The function λk(t; X (2)i , vi , νk, γk) is the instantaneous failure rate from cause k at
time t given the vector of covariates X (2)i (t) and the latent unknown factor vi , in the
presence of all other failure types. The regression coefficient νk represents the effect of
the latent variable vi with ν1 set to 1 to ensure identifiability. The parameter γk repre-
sents the effects of the observed covariates X (2)i (t) on cause k. We further assume that
the kth baseline hazard is a step function, λ0k(t) = λ(s)0k , for t (s−1)k < t ≤ t (s)k , where
0 < t (1)k < · · · < t (S
k )
k < ∞ is a partition of (0,∞) and Sk indicates the number of
steps for the kth baseline hazard.
2.3 Variance–covariance regression sub-model
We model the association between the longitudinal and survival sub-models by assum-



















Similar to Pourahmadi (1999), we model the covariance matrices Σi through a mod-
ified Cholesky decomposition MiΣi MTi = Hi , where Hi is a diagonal matrix with
positive entries and Mi is the lower triangular matrix with −φi, jl as its ( j, l)th entry.
This decomposition has a clear statistical interpretation: the below-diagonal entries of





φi, jl W jl + ei j , j = 1, . . . , q + 1. (4)
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The diagonal entries of Hi are the innovation variances (IV) h2i j = var(ei j ) and we
have cov(ei j , e jk) = 0 if j = k (1 ≤ j , k ≤ q + 1 and i = 1, . . . , m). The GARPs
and the logarithms of the IVs are modeled with linear and log link functions:
{
φi, jl = aTi, jlη1 for i = 1, . . . , m
log h2i j = bTi jη2 j = 1, . . . , q + 1, l = 1, . . . , j − 1
(5)
where ai, jl and bi j are covariates, and η1 and η2 are low-dimensional parameter
vectors. For example, ai, jl and bi j may contain group indicators, implying that the
random effects covariances are heterogeneous. The homogeneous random effects
assumption in existing joint models becomes a testable assumption within our model
framework. Furthermore, the resulting estimated covariance matrix is guaranteed to
be positive definite. The latent association between the longitudinal measurements
and survival outcomes can be assessed by testing the hypothesis ΣUvi = 0. Finally,
we assume that conditional on all the covariates and random effects, the longitudinal
measurements and the competing risks survival data are independent.
Remark: Choice of design vectors for GARP/IV parameters As we mentioned earlier,
the choice of covariate vectors ai, jl and bi, j are flexible. For example, a 3-dimen-
sional random effects variance–covariance matrix has six parameters. We can model
the homogeneous unstructured covariance matrix by setting ai, jl = bi j = 1 for
all j = 1, . . . , 3, l = 1, . . . , j − 1. If we assume the design vectors contain sub-
ject-dependent covariate, say, a group indicator (G), the unstructured heterogeneous
covariance matrix can be modeled with ai, jl = bi j = (1, Gi ) for all j = 1, . . . , 3,
l = 1, . . . , j − 1; that is,
{
ai = (ai, jl) = (1, Gi , 1, Gi , 1, Gi )T ; η1 = (ηI nt11 , ηG11, ηI nt12 , ηG12, ηI nt13 , ηG13)T
bi = (bi j ) = (1, Gi , 1, Gi , 1, Gi )T ; η2 = (ηI nt21 , ηG21, ηI nt22 , ηG22, ηI nt23 , ηG23)T .
(6)
When there are high-dimensional random effects with limited data, one can impose a
restricted covariance structure and assume some of the GARP are the same to reduce
the number of parameters.
3 Estimation and inference
The standard maximum likelihood method involves integrating out latent variables
from the log-likelihood function which is difficult when dealing with high-dimen-
sional variables. We develop a Bayesian estimation procedure and a Markov chain
Monte Carlo (MCMC) method for estimation and inference.
3.1 Likelihood
Suppose the longitudinal outcome Yi (t) is observed at time points ti j for j =
1, . . . , ni , and denote Yi = (Yi1, . . . , Yini ). Let Ω = {β, σ 2, γ, ν, λ0, η1, η2},




A general joint model for longitudinal measurements and competing risks survival data 85
It is convenient to work directly with the joint distribution of the observed data
(Y, C) and the unobservable random effects W , conditional on Ω , which facilitates
the MCMC implementation. The conditional joint density of (Y, C) and W is:
p(Y, C, W |Ω) =
m∏
i=1















































λk(Ti ) = λ0k(Ti ) exp
{









X (2)i (t)γk + νkvi
)
dt. (9)
Under the piecewise constant hazard assumption,



















3.2 Priors and MCMC sampling procedure
We assume independent priors for Ω . We use Normal priors for the parameters β, γ ,
ν, η1 and η2, leading to conjugate posteriors for β and some components of the η1.
We use an inverse Gamma prior for the measurement error variance σ 2 and a gamma
prior for each step of the kth baseline hazard function λ0k by which conjugate posterior
distributions are easy to obtain.
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Markov Chain Monte Carlo (MCMC) methods are used for posterior sampling.
It involves sampling directly from the full conditional distribution, Metropolis–
Hastings (MH) sampling (Hastings 1970; Chib and Greenberg 1995) and adaptive
rejection sampling (ARS) (Gilks and Wild 1992). Since the full conditional distri-
butions of the parameters β, σ 2, and λ(s)0k , (s = 1, . . . , Sg , k = 1, . . . , g) are stan-
dard distributions, drawing random variates from their full conditional distributions is
straightforward. For the rest of the parameters and random effects (Ui , vi ), we either
use a Metropolis–Hastings step with the normal approximation to the full conditional
distribution as the candidate distribution or apply the ARS technique. The technical
details on the sampling distributions are given in the Appendix.
The initial values of the parameters for sampling are obtained by modeling the
longitudinal data and survival data separately by a linear mixed model and a Cox
proportional hazards model. The initial value for λ(s)0k (s = 1, . . . , Sk , k = 1, . . . , g)
can be obtained by drawing a random variate from the gamma full conditional dis-
tribution described in the Appendix. We estimate the parameters by their posterior
medians. Approximate 95% probability intervals are based on 2.5th percentile and
97.5th percentile. Standard errors are obtained from the standard deviations of the
posterior samples. The convergence of the Gibbs sampler is monitored by examining
time series plots of the parameters over iteration and the Gelman and Rubin (1992)
approach of using multiple chains.
4 Application
We analyze the data from a scleroderma lung study (SLS) (Tashkin et al. 2006) with
our proposed joint model. The study enrolled 158 patients with scleroderma-related
interstitial lung disease, randomized to receive either CYC (79 patients) or identical
appearing placebo (79 patients) for 12 months. An additional year of follow-up was
performed to determine if CYC effects persisted after treatment. The primary outcome
is forced vital capacity (FVC, % predicted), measured at 3-month intervals from the
baseline. We are interested in evaluating if oral cyclophosphamide (CYC) can either
improve the %FVC level of a patient or decrease the risk of treatment failure or death.
Since the full dose of CYC is not reached until month 6, our analysis is based on
6–24 months %FVC scores which includes 140 subjects. We observe 14 treatment
failures or deaths, 32 informative and 5 noninformative dropouts. A dropout is non-
informative if there is no evidence showing that the dropout is related to the disease
or the treatment, and informative otherwise. Since the informative dropout is related
to the patient’s disease condition, it not only causes non-ignorable missing data in
%FVC, but also is an informatively censored event for treatment failure or death.
We consider two baseline factors in our joint model when assessing the CYC treat-
ment effects: baseline %FVC (FVC0), and lung fibrosis (FIB0). It is suggested by cli-
nicians that the beneficial effects of CYC on pulmonary function continue to increase
after stopping treatment at 12 months and eventually begin to wane after 18 months.
Therefore, we fit the following linear spline mixed effects model with change point at
month 18 for longitudinal measurements %FVC:
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%FVCi j = β0 + β1FVC0i + β2FIB0i + β3CYCi + β4Timei j + β5(Timei j − 18)+
+β6FVC0i × CYCi + β7FIB0i × CYCi + β8Timei j × CYCi
+β9(Timei j − 18)+ × CYCi + Zi jUi + i j (11)
where Ui is the subject-specific random effect and the i j is the mutually independent
measurement error.
We consider multiple choices for random effects covariates Zi and select the model
based on the Deviance Information Criterion (DIC) (Spiegelhalter et al. 2002). The
DIC has the advantage of being easy to compute using output from a Gibbs sampler
and has a similar form as the Akaika Information Criterion (AIC): a goodness-of-fit
term measured by deviance evaluated at the posterior mean of the parameters, and
a penalty term defined by twice of the effective number of parameters. The effective
number of parameters is computed as the mean deviance minus the deviance evaluated
at the posterior mean. That is,
DIC = dev(Ω) + 2pD (12)
where Ω is the posterior mean of parameter Ω , pD = dev − dev(Ω) and dev is the
posterior mean of the deviance (the average of the deviances calculated using the esti-
mated parameters at each step of the MCMC sampler). Based on the form of the DIC,
it is obvious that the smaller the DIC value, the better the model proposed. We note
that there are several versions of DIC for missing data models (Celeux et al. 2006;
Chen 2006). Here we use the DIC constructed from the conditional distribution while
treating both Ω and W as parameters because it is easy to compute. We conduct a
small simulation to evaluate the DIC which selects 147 times out of 200 datasets and
the effective dimension is always positive.
A cause-specific competing risks sub-model is applied to model disease-related
dropout (risk 1) and treatment failure or death (risk 2):
λ1(t) = λ01(t) exp(γ11FVC0i + γ12FIB0i + γ13CYCi + γ14FVC0i × CYCi
+γ15FIB0i × CYCi + vi ) (13)
and
λ2(t) = λ02(t) exp(γ21FVC0i + γ22FIB0i + γ23CYCi + γ24FVC0i × CYCi
+γ25FIB0i × CYCi + ν2vi ). (14)
The latent variables from both sub-models are assumed to have a multivariate normal
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We test the homogeneous random effects covariance matrix assumption by con-
sidering subject-dependent covariates for ai jl and bi j . Specifically, we choose ai jl =
bi j = (1, CYCi ), which allows heterogeneous covariance matrices for different treat-
ment groups, and test the null hypothesis by examining if the 95% credible interval of
CYC effects contains zero for all the GARP and IV parameters.
A 3-step baseline hazard function, with the time points defining the steps being
equally split percentiles of the observed event times, is utilized for the informatively
censored events and the event of treatment failure or death. Sensitivity analyses with
4- and 5-step baseline hazard functions are conducted and show no significant dif-
ference. We apply independent noninformative prior distributions for all the param-
eters which all assumed to have relatively large variances. The corresponding priors
for the parameters are β0 ∼ N (70, 103) and βl ∼ N (0, 103) for l = 1, . . . , 9;
σ 2 ∼ I G(10−3, 10−3); γkr ∼ N (0, 103) for k = 1, 2 and r = 1, . . . , 5; λ(s)0k ∼
Γ (10−3, 10−3) for s = 1, . . . , Sk and S1 = S2 = 3; ν2 ∼ N (0, 105); and each
element of η1 and η2 ∼ N (0, 105).
Table 1 summarizes the covariance matrix parameters of different models, each was
based on 30,000 iterations of MCMC sampling chains following a 15,000-iteration
“burn-in” period. Since we include baseline %FVC as a fixed effect covariate, we do
not consider random intercept to avoid possible confounding effects. We consider a
one-random-slope (before 18 months) model, a structured two-random-slope model
assuming the entries of last row in matrix Mi from the decomposition are the same, and
an unstructured two-random-slope model. The structured random effects covariance
matrix model might be useful when dealing with high-dimensional random effects
model but with limited data. For the last element of the innovation variance parameter,
we do not include the CYC effects due to the convergence issue. It is clear that none
of the 95% credible intervals for CYC exclude zero. Therefore, we don’t have suffi-
cient evidence to reject the homogeneous random effects covariances assumption. All
the effective numbers of parameters (pD) are positive which is not an indication of
possibly poor fit between the models and the data (Spiegelhalter et al. 2002). The con-
ditional DIC we use tends to produce increasing pDs for increasing model complexity
as suggested by Celeux et al. (2006). The two-random-slope model with unstructured
covariance matrix has the smallest DIC, indicating that it might provide the best fit for
the SLS data. Combining the earlier results, we chose the homogenous two-random-
slope model with unstructured covariance matrix as our final model and its covariance
parameters and DIC values are listed in the last column of Table 1.
The results of the selected two-random-slope model are summarized in Table 2.
For comparison purposes, we perform separate analysis of the two endpoints, which
is done by fitting a linear mixed model with two random slopes (11) for %FVC and a
cause-specific hazards frailty model for the competing risks failure time data (13), (14),
respectively. The two methods produce similar point estimates and credible intervals
for baseline %FVC, lung fibrosis and their interactions with CYC, but give different
results on the interactions of CYC and time trends. With the joint model, the signifi-
cance of the interactions between CYC and time trends indicates that the developing
trends of %FVC in the two groups are different. The %FVC declines for the placebo
group (β4 = −0.12) but increases for the CYC group (β4 + β8 = 0.14) in the first 18
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Table 2 Analysis of SLS data using the unstructured homogeneous two-random-slope model
Joint analysis Separate analysis
Estimate (95% CI) Estimate (95% CI)
Longitudinal outcome %FVC
Int (β0) 65.33 (64.72, 67.87) 65.94 (64.41, 67.47)
FVC0 (β1) 0.89 (0.80, 0.99)† 0.89 (0.79, 0.99)†
FIB0 (β2) −1.85 (−2.94, −0.79)† −1.86 (−2.94, −0.78)†
CYC (β3) −0.98 (−3.18, 1.26) −0.76 (−2.94, 1.42)
Time (β4) −0.12 (−0.29, 0.06) −0.05 (−0.23, 0.13)
Time18 (β5) 0.27 (−0.17, 0.72) 0.11 (−0.34, 0.56)
FVC0 × CYC (β6) 0.14 (0.00, 0.28)† 0.14 (0.00, 0.28)†
FIB0 × CYC (β7) 1.74 (0.13, 3.27 )† 1.78 (0.23, 3.33)†
Time × CYC (β8) 0.26 (0.01, 0.50)† 0.21 (−0.04, 0.46)
Time18 × CYC (β9) −0.72 (−1.33, −0.08)† −0.64 (−1.29, 0.00)
σ 2 21.55 (19.23, 24.25) 21.28 (18.80, 23.76)
ΣU11 0.27 (0.20, 0.36) 0.25 (0.18, 0.32)
ΣU12 −0.31 (−0.53, −0.14) −0.31 (−0.49, −0.12)
ΣU22 1.29 (0.70, 2.14) 1.34 (0.67, 2.00)
p-value for H0 : β3 = β6 = β7 = β8 = β9 = 0 0.01 0.03
Cause-specific hazards (time to informative dropout)
FVC0 (γ11) −0.06 (−0.12, −0.01)† −0.06 (−0.12,−0.00)†
FIB0 (γ12) 0.22 (−0.27, 0.78) 0.20 (−0.35, 0.75)
CYC (γ13) 0.23 (−0.60, 1.12) 0.40 (−0.46, 1.26)
FVC0 × CYC (γ14) 0.10(0.03, 0.18)† 0.09(0.03, 0.15)†
FIB0 × CYC (γ15) 0.13 (−0.60, 0.83) 0.07 (−0.64, 0.76)
p-value for H01 : γ13 = γ14 = γ15 = 0 0.08 0.07
Cause-specific hazards (time to treatment failure or death)
FVC0 (γ21) 0.02 (−0.07, 0.09) 0.03 (−0.07, 0.13)
FIB0 (γ22) 0.29 (−0.62, 1.19) 0.28 (−0.80, 1.36)
CYC (γ23) −1.33 (−3.44, 0.21) −1.14 (−3.26, 0.98)
FVC0 × CYC (γ24) −0.07 (−0.21, 0.06) −0.08 (−0.24, 0.08)
FIB0 × CYC (γ25) −0.58 (−2.31, 0.91) −0.88 (−2.78, 1.02)
p-value for H02 : γ23 = γ24 = γ25 = 0 0.39 0.48
Random effects for survival endpoint
ν2 3.04 (1.27, 7.65) −0.31 (−79.80, 81.16)
σ 2v 0.38 (0.07, 1.42) 0.04 (0.00, 0.40)
Covariance of Ui and vi
ΣU1v −0.25 (−0.51, −0.09) –
ΣU2v 0.60 (0.21, 1.33) –
† p-Value <0.05
123
A general joint model for longitudinal measurements and competing risks survival data 91
months. After 18 months the %FVC declines for the CYC group (β4 +β5 +β8 +β9 =
−0.45) since the CYC effects decrease gradually after the treatment stops, while a
positive slope is found for the placebo group (β4 + β5 = 0.15). However, none of
the time trends is significantly different from zero. The difference might be explained
by the significant covariances ΣU1v and ΣU2v between the random slopes in the
longitudinal model and the latent variable of the survival model, which indicates
dependence between the longitudinal measurement %FVC and the survival process.
We also observe significantly positive coefficient ν2 which shows that there is a latent
association between the two competing risks. The negative sign of ΣU1v and positive
sign of ΣU2v together with positive ν2 indicate that in the first 18 months, there tends
to be a lower risk for both treatment failure or death and informatively censored events
due to dropout for patients with higher than average increasing rate of %FVC over
time; after 18 months, the trend is reversed due to the negative association between
the two slopes. The consequence of such informative dropout process results in biased
estimates in time trends and attenuated slope changes comparing the CYC group with
the placebo group for the separate analysis. The results are confirmed by the simulation
study in the later section. The overall effects of treatment CYC on %FVC scores are
evaluated by testing the null hypothesis H0 : β3 = β6 = β7 = β8 = β9 = 0 which
yields a p-value 0.01 for the joint model and 0.03 for the separate model.
When modeling the competing risks survival data, the two methods produce similar
point estimates and CIs for most parameters and identify the same set of significant
effects. The joint model is able to identify the relationship (ν2) between the two com-
peting risks much better than the separate model since the separate model does not
rely on the additional information from the longitudinal endpoints. We note that, in
our second simulation study in the next section, the estimate for ν2 is not reliable under
the current sample size and event rates even for the joint model. Hence we would not
overinterpret the quantity in this application. However, the simulation also suggests
that the bias of ν2 does not seem to affect the estimation of other parameters in the joint
model. No significant overall effects of CYC are identified for the time to treatment
failure or death by testing the null hypothesis H02 : γ23 = γ24 = γ25 = 0 because of
the relatively short follow-up period.
5 Simulation studies
We carry out two simulation studies to assess the performance of our method. In the
first simulation, the data are generated with heterogeneous covariance matrices and
we want to show how the parameter estimates and standard errors would be affected
if we ignore the heterogeneity. The longitudinal measurements are simulated from the
following model:
Yi j = β0 + β1ti j + β2 X2i + Ui ti j + i j (15)
where ti j = 0, 0.15, 0.3, . . ., 3, is the scheduled visit time and X2i ∼ Bernoulli(0.5) is
a group indicator. The measurement error i j ∼ N (0, 5). We simulate two competing
risks failure times with the following cause-specific hazards:
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Table 3 Comparison of simulated bias, standard error (SE) and coverage probability (CP) between two
homogeneous (incorrect) models and a heterogeneous (correct) model (sample size=200)
Homogeneousa Homogeneous Heterogeneous
m Parameter True Bias SE CP Bias SE CP Bias SE CP
200 Longitudinal
β0 10 0.023 0.055 0.935 0.017 0.054 0.925 0.007 0.057 0.914
β1 1.5 −0.029 0.069 0.950 −0.019 0.065 0.960 −0.010 0.073 0.921
β2 −1 0.029 0.173 0.885 0.036 0.215 0.860 −0.029 0.117 0.911
σ 2 1 −0.002 0.30 0.965 0.001 0.029 0.965 0.002 0.033 0.938
σ 2u1 2.5 − – – − – – −0.001 0.525 0.942
σ 2u0 0.5 − – – − – – 0.041 0.182 0.935
Survival
γ11 0.8 −0.26 0.137 0.885 0.011 0.158 0.920 −0.006 0.139 0.925
γ12 −1 0.133 0.289 0.840 0.047 0.416 0.880 −0.024 0.302 0.932
γ21 0.5 −0.066 0.163 0.910 −0.066 0.195 0.875 −0.026 0.150 0.928
γ22 −1 0.378 0.347 0.755 0.350 0.426 0.810 −0.007 0.359 0.932
ν2 1.5 −0.281 1.049 0.715 −0.352 1.891 0.715 −0.116 0.863 0.912
σ 2v1 1 − – – − – – 0.026 0.706 0.825
σ 2v0 0.5 − – – − – – −0.048 0.301 0.801
Joint covariances
σuv1 1.5 − – – − – – −0.216 0.785 0.805
σuv0 −0.4 − – – − – – 0.080 0.247 0.787
a Homogeneous model from Hu et al. (2009)
The bold numbers represent relatively large biases
λ1(t; X1i , X2i , υi , γ1) = λ01(t) exp{γ11 X1i + γ12 X2i + υi } (16)
λ2(t; X1i , X2i , ui , γ2, ν2) = λ02(t) exp{γ21 X1i + γ22 X2i + ν2υi }
where X1 ∼ N (2, 1.0), and X2 are shared with the longitudinal model. We use con-
stant baseline hazards of 0.12 and 0.25 for risk 1 and risk 2 respectively to generate
the event time data. The random effects are generated from the multivariate normal
distribution with covariance matrices Σi which are decomposed into the GARPs and
IVs modeled with covariates ai jl = bi j = (1, X2i ). In other words, the covariance
matrices are different in the two groups: strong positive correlation in one group and
strong negative correlation in the other. The parameters are given in Table 3. With this
setup, the rate of risk 1 is approximately 0.40, the rate of risk 2 is 0.38 and censoring
rate is 0.22. Longitudinal responses are missing after the observed or censored event
times. The average number of total longitudinal observations is 11.6 per subject. We
use N (0, 105) priors for each component of β, γ , ν, η1 and η2, I G(10−3, 10−3) for
σ 2, and Γ (10−3, 10−3) for λ0. The simulation is based on 200 Monte Carlo samples
with sample size of 200 and 500. The MCMC sampling in all simulation studies is run
using 5, 000 iterations, and the estimation results are based on the last 2, 500 iterations.
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Table 4 Comparison of simulated bias, standard error (SE) and coverage probability (CP) between a
homogeneous (incorrect) model and a heterogeneous (correct) model (sample size = 500)
Homogeneousa Homogeneous Heterogeneous
m Parameter True Bias SE CP Bias SE CP Bias SE CP
500 Longitudinal
β0 10 0.024 0.035 0.895 0.024 0.035 0.893 0.001 0.037 0.916
β1 1.5 −0.032 0.044 0.875 −0.031 0.043 0.902 −0.002 0.045 0.948
β2 −1 0.055 0.113 0.835 0.053 0.127 0.907 0.008 0.087 0.924
σ 2 1 −0.001 0.019 0.960 −0.001 0.019 0.937 0.001 0.019 0.948
σ 2u1 2.5 − – – − – – 0.007 0.346 0.920
σ 2u0 0.5 − – – − – – 0.017 0.105 0.913
Survival
γ11 0.8 −0.004 0.085 0.890 −0.017 0.091 0.917 −0.005 0.087 0.920
γ12 −1 0.153 0.177 0.815 0.162 0.219 0.815 −0.016 0.171 0.937
γ21 0.5 −0.001 0.099 0.900 −0.033 0.101 0.922 −0.012 0.093 0.920
γ22 −1 0.336 0.211 0.605 0.346 0.216 0.649 −0.021 0.207 0.920
ν2 1.5 0.102 0.525 0.825 0.152 1.516 0.809 −0.075 0.843 0.937
σ 2v1 1 − – – − – – −0.034 0.354 0.906
σ 2v0 0.5 − – – − – – −0.030 0.182 0.899
Joint covariances
σuv1 1.5 − – – − – – −0.064 0.398 0.923
σuv0 −0.4 − – – − – – 0.009 0.145 0.882
a Homogeneous model from Hu et al. (2009)
The bold numbers represent relatively large biases
We analyze the simulated data with a joint model that models the covariance
matrices with subject-specific covariates (heterogeneous) and a joint model with sub-
ject-independent covariates (homogeneous). We also compare the results with the
homogeneous model proposed by Hu et al. (2009). Tables 3 and 4 report the biases,
estimated standard errors (the median of estimated standard error), and coverage rates
of the 95% credible intervals. The parameters η1 and η2 are transformed back to vari-
ance–covariance parameters in the table. It is seen that the heterogeneous joint model
gives almost unbiased estimates for all the parameters. Our method for the homoge-
neous model performed similarly to Hu et al. (2009). Both homogeneous joint analyses
lead to large bias in some of the parameter estimates including γ12, γ22 and ν2, which
indicates that we may obtain biased parameter estimates for the survival endpoint
when combining the information of the longitudinal outcome if the correlation of the
two endpoints is incorrectly modeled. Therefore, ignoring the heterogeneity can result
in biased estimates and invalid inference.
We conduct the second simulation by generating data with structures similar to the
SLS. The longitudinal measurements and the competing risks event times are sim-
ulated from model (11–14) with Zi j = ([Timei j , Time18i j ]), where the covariates
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are generated from distributions close to what we observe in the real data. All the
parameters for the joint model are set to the estimated values from the joint analysis
for SLS in Table 2. Weibull distributions are used as the true baseline hazard function
which produce similar risk rates and censoring rate to those in SLS. The results of the
joint model and the separate analysis are compared in Table 5 using 200 simulated
datasets with a sample size m = 140. MCMC sampling is run in 10,000 iterations, and
the estimation results were based on the last 5,000 iterations. It is shown that the joint
model produces good point estimates and coverage rates for most of the parameters
in the longitudinal sub-model except for the time trend after 18 months (β5) and the
corresponding variance (ΣU22). The separate analysis gives biased estimates for both
time trends and their corresponding variances. These biases do not decrease even for a
large sample size of 500 (simulation results are not reported here) since the biases are
the consequences of the informative dropout process, which cannot be accounted for
by the linear mixed effects alone. In contrast, the biases in the joint model are much
improved with increased sample size. The random effects coefficient ν2 and frailty σ 2v
and their standard errors are poorly estimated by the separate competing risks models.
The joint model gives biased estimate for ν2 as well, which suggests that with a small
sample size of 140 and low event rates (10% for risk 1 and 23% for risk 2), even the
joint analysis may not provide good estimates for the frailty at the survival endpoint.
6 Discussion
For simplicity, we assume in our model that the measurement errors are mutually
independent and normally distributed with constant variance. This assumption can be
weakened and our method can be modified to handle correlated normal random errors.
Our model also assumes that the longitudinal sub-model and survival sub-model are
independent conditional on the observed data and latent variables. This may not be
satisfied in a real study such as the SLS, in which one of the risks in the survival
endpoint, treatment failure or death, is partly determined by the longitudinal outcome
%FVC. We did some sensitivity analyses and found that our model is robust for mild
violation of the independence assumption.
Our model can be extended to clustered data. Frequently, clustered data arises from
multi-site clinical trials or from studies across families, in which each site or fam-
ily can be viewed as a cluster. The cluster effect can be conveniently incorporated
as a random effect or as design vectors for the GARP/IV parameters to take into
account the heterogeneity across the cluster. Similarly, our method can be extended
to recurrent event data where each subject may repeatedly experience a certain phe-
nomenon. In addition, within our joint model framework, the linear mixed sub-model
can be extended to the generalized linear mixed effects model (Diggle et al. 2002) to
handle non-normally distributed data, such as binomial or Poisson outcomes. Due to
the complexity of the likelihood function in both GLMMs and joint models, only a
few papers discussed such a generalized joint model framework (Molenberghs et al.
1997; Faucett et al. 1998; Larsen 2005; Yao 2008). Although in our joint model the
posterior sampling distributions for the fixed and random effects in the longitudinal
sub-model need to be changed, the parameters in the survival sub-model and the joint
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Table 5 Comparison of simulated bias, standard error (SE) and coverage probability (CP) between joint
and separate analyses (sample size=140)
Joint Separate
Parameter True Bias SE CP Bias SE CP
Longitudinal
Fixed effects
β0 66.33 0.004 0.765 0.975 0.459 0.768 0.925
β1 0.89 −0.002 0.051 0.955 0.002 0.051 0.940
β2 −1.85 −0.028 0.597 0.925 −0.030 0.592 0.940
β3 −0.98 −0.049 1.031 0.955 0.210 1.019 0.960
β4 −0.12 −0.002 0.099 0.935 0.082 0.096 0.815
β5 0.27 −0.111 0.278 0.900 −0.299 0.239 0.775
β6 0.14 −0.002 0.073 0.950 −0.003 0.072 0.935
β7 1.74 0.026 0.839 0.945 0.032 0.832 0.935
β8 0.26 −0.006 0.130 0.940 −0.036 0.127 0.945
β9 −0.72 0.040 0.337 0.935 0.101 0.327 0.920
Random effects
σ 2 21.55 0.049 1.357 0.935 0.041 1.310 0.940
ΣU11 0.27 −0.001 0.038 0.965 −0.022 0.035 0.855
ΣU12 −0.31 0.060 0.095 0.860 0.066 0.083 0.860
ΣU22 1.29 −0.284 0.401 0.790 0.235 0.345 0.790
Competing risks
Fixed effects
γ11 −0.06 −0.004 0.030 0.950 0.005 0.025 0.940
γ12 0.22 0.077 0.320 0.925 0.017 0.270 0.930
γ13 0.23 0.011 0.518 0.920 0.038 0.448 0.935
γ14 0.10 0.005 0.042 0.950 −0.010 0.031 0.965
γ15 0.13 0.063 0.434 0.920 −0.064 0.345 0.955
γ21 0.02 −0.009 0.041 0.945 −0.008 0.029 0.945
γ22 0.29 0.055 0.473 0.925 −0.061 0.356 0.925
γ23 −1.33 −0.052 1.107 0.925 −0.098 1.049 0.915
γ24 −0.07 0.003 0.075 0.960 0.010 0.059 0.995
γ25 −0.58 −0.010 0.891 0.940 0.095 0.805 0.965
Random effects
ν2 3.04 −0.456 1.043 0.925 −0.414 3.212 1.000
σ 2v 0.38 0.076 0.728 0.995 −0.333 0.058 0.285
Joint covariances
ΣU1v −0.25 −0.100 0.128 0.970 − − −
ΣU2v 0.60 −0.022 0.418 0.945 − − −
The bold numbers represent relatively large biases
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variance–covariances parameters can be sampled with our described algorithm. One
of the possible approaches to sample the parameters in the GLMM sub-model is to
update the fixed and random effects by constructing a normal proposal distribution
with mean and variance from a single iteration of weighted least squares based on the
previous value (Gamerman 1997).
We finally note that the modified Cholesky decomposition can provide an uncon-
strained and statistically meaningful reparameterization of a covariance matrix, but at
the expense of imposing an order among the underlying random variables. Despite of
this shortcoming, it has been used effectively in various applications including mul-
tivariate quality control, multivariate time series, finance and random effects models
(Pourahmadi 2007).
Appendix
This section provides details for the full conditional distributions of the parameters
used in the Gibbs sampling algorithm. We use p(.) and p(.|.) to denote marginal and
conditional densities, respectively. We denote the prior distribution by p0(.). Based
on the modified Cholesky decomposition, the random effects vi can be written as
vi = ∑ql=1 aTiqlη1Uil + ei,q+1 where ei,q+1 ∼ N (0, exp(bTi,q+1η2)). Instead of sam-
pling vi directly, we sample ei,q+1, leading to a faster convergence rate.
























2. Sample σ 2 from
















3. Sample the random effects Ui from
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, μUi |Yi = ΣUi |Yi
[










i is a q ×q matrix consisting of the first q columns and rows of
Mi , H∗i is a q ×q matrix consisting of the first q columns and rows of Hi . We use
the one-step Metropolis–Hastings algorithm to obtain the update in the sampling
sequence with the normal density from the longitudinal data as the proposal den-
sity. The random effects Ui is obtained by first sampling a random variable form
the conditional density based on the longitudinal data and then using the condi-
tional likelihood contribution from the survival data to determine the acceptance
of the new draw.



























νk I (Di=k)−Hk(Ti )
}
p0(η1),
where Qi is a q×q1 matrix with first row Qi1 = 0 and j th row Qi j = ∑ j−1l=1 aTi jlUil
for j = 2, . . . , q. We sample η1 in two steps: sample the entries only involves Ui
from the normal conditional density, sample the entries involves Ui and vi with
ARS.




















+ bTi,q+1η2 + e2i,q+1 exp(−bTi,q+1η2)
)]
p0(η2).
We use a Metropolis–Hastings step with a normal approximation to the full con-
ditional as the candidate distribution. For details, see Daniels and Pourahmadi
(2002).
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6. Sample γkr , k = 1, . . . , g, r = 1, . . . , R from











We use a Metropolis–Hastings step within the single component sampler to update
the values of these parameters. For each of these parameters, we propose a normal
density as the proposal density, which has the current value of the parameter as
its mean and its standard deviation is set equal to four times the standard error
of a maximum partial likelihood estimate from a standard Cox model (Wang and
Taylor 2001).
7. Sample νk with ARS from
























8. Sample ei,q+1 (i = 1, . . . , m) from
p(ei,q+1|.) ∝ N (0, exp(bTi,q+1η2)) ×
g∏
k=1
exp[ei,q+1νk I (Di = k) − Hk(Ti )].
The sample is obtained by first sampling a candidate from the normal densities
as its assumption and then using the conditional likelihood contribution from the
survival data to determine the acceptance of the new draw.
9. Sample each piece of λ0k (k = 1, . . . , g) from
p(λ(s)0k |.) ∝ Γ (αsk, βsk )p0(λ(s)0k ),
where αsk =
∑m
i=1 I (Di = k, t (s−1)k < Ti ≤ t (s)k ) + 1 indicates the number
of events occurring in the time interval (t (s−1)k , t
(s)
k ], and βsk =
∑m
i=1 I (Ti >
t (s−1)k )




i + νkvi )dt , for s = 1, . . . , Sk .
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